Last reviewed · How we verify
Jaktinib Hydrochloride Tablets
At a glance
| Generic name | Jaktinib Hydrochloride Tablets |
|---|---|
| Also known as | Jaktinib |
| Sponsor | Suzhou Zelgen Biopharmaceuticals Co.,Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Phase III Study of Jaktinib in Adults With Moderate and Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Effect of Jaktinib on QT/QTc Interval in Healthy Participants (PHASE1)
- Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis (PHASE2)
- Efficacy and Safety of Jaktinib in Participants With Severe Novel Coronavirus Pneumonia(COVID-19) (PHASE2)
- A Safety and Tolerability Study of Jaktinib (PHASE1)
- A Study of Jaktinib for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease. (PHASE2)
- A Phase III Extended Clinical Trial of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis (PHASE3)
- A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: